XKRX
950220
Market cap14mUSD
Apr 03, Last price
1,060.00KRW
1D
3.72%
1Q
-10.17%
IPO
-92.46%
Name
Neoimmunetech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-53.40b
L-11.59%
CFO
-49.76b
L+17.35%
Profile
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 29,548,150 | 36,985,699 | |||
Unusual Expense (Income) | |||||
NOPBT | (29,548,150) | (36,985,699) | |||
NOPBT Margin | |||||
Operating Taxes | 101,299 | 116,414 | |||
Tax Rate | |||||
NOPAT | (29,649,449) | (37,102,113) | |||
Net income | (53,404,510) -11.59% | (60,405,625) 15.10% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 41,261 | 402,555 | |||
BB yield | -0.02% | -0.51% | |||
| Debt | |||||
Debt current | 1,352,622 | 1,279,295 | |||
Long-term debt | 6,463,214 | 8,423,599 | |||
Deferred revenue | |||||
Other long-term liabilities | 213,934 | 206,766 | |||
Net debt | (63,450,439) | (107,543,230) | |||
| Cash flow | |||||
Cash from operating activities | (49,760,750) | (42,404,803) | |||
CAPEX | (791) | (2,476,539) | |||
Cash from investing activities | 2,087 | (3,150,258) | |||
Cash from financing activities | (1,136) | (633,323) | |||
FCF | (28,001,021) | (37,443,341) | |||
| Balance | |||||
Cash | 69,072,408 | 117,075,102 | |||
Long term investments | 2,193,867 | 171,022 | |||
Excess cash | 71,266,275 | 117,246,124 | |||
Stockholders' equity | (246,514,445) | (170,955,181) | |||
Invested Capital | 325,492,669 | 295,610,160 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 98,849 | 19,728 | |||
Price | 2,025.00 -49.31% | 3,995.00 -61.40% | |||
Market cap | 200,170,217 153.99% | 78,811,390 -59.98% | |||
EV | 136,719,778 | (28,731,840) | |||
EBITDA | (26,338,569) | (34,183,617) | |||
EV/EBITDA | 0.84 | ||||
Interest | 225,280 | 261,390 | |||
Interest/NOPBT | |||||